Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Based on the dramatic fat reduction (up to 82.4%) and enzyme normalization (70-80%), researchers estimate a high probability of NASH resolution, but this needs confirmation in a dedicated Phase 3 trial with biopsy endpoints (expected 2027-2030)
Product Attributes Customization Available Certification MSDS, GMP Age Group Adults Model NO
The GLP-1/GIP dual-receptor agonist DA5-CH inhibits the NF-B inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01
Tirzepatide is a once-weekly injection used for adults who are considered obese or overweight
US$ 26.67
US$ 29.13
US$ 24.21
US$ 28.99
US$ 23.50
